CMMB: Morgan Stanley Drops Below 5 % Ownership in Schedule 13G/A

Rhea-AI Filing Summary

Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.

• Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
• Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
• Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
• Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
• No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
• The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).

The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.

Positive

• None.

Negative

• Morgan Stanley and Morgan Stanley & Co. LLC reduced their combined ownership in Chemomab below the critical 5 % threshold, potentially signaling diminished institutional commitment.

Insights

Buy-side Portfolio Manager

TL;DR: Morgan Stanley trims Chemomab stake below 5 %, lowering perceived institutional sponsorship.

The filing shows the Morgan Stanley complex now owns 3.2 % of Chemomab versus >5 % previously. Crossing below the 5 % level reduces disclosure obligations and may indicate profit-taking or risk management following earlier biotech volatility. While 3.2 % remains material for a micro-cap, the downgrade in ownership could pressure sentiment as other funds often track large holders. No new financing, lock-ups, or strategic agreements accompany the change, so the impact is purely ownership-based. Overall, the event is modestly negative but not thesis-breaking.

Corporate Governance Analyst

TL;DR: Technical filing; reflects compliance with Section 13 rules, limited governance impact.

This 13G/A is primarily administrative—Morgan Stanley’s ownership dropped below the 5 % threshold, requiring an amendment within ten days. The firm still discloses shared voting/dispositive powers, suggesting holdings are spread across trading desks rather than a strategic position. No attempt to influence control is stated (certification under Rule 13d-1(b)). For governance watchers, the key takeaway is that Morgan Stanley is now a sub-5 % passive holder; board composition and control dynamics remain unchanged. Consequently, the filing is not materially impactful to control structure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Chemomab Therapeutics Ltd.

(Name of Issuer)

Ordinary Shares / American Depositary Shares

(Title of Class of Securities)

16385C104

(CUSIP Number)

07/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 16385C104

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,213,260.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,213,260.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,213,260.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

CUSIP No. 16385C104

1

Names of Reporting Persons

Morgan Stanley & Co. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,275,360.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,275,360.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,275,360.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.2 %

12

Type of Reporting Person (See Instructions)

BD, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: KIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3, 6158002
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley & Co. LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Ordinary Shares / American Depositary Shares
(e)	CUSIP No.: 16385C104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 3.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/07/2025

Morgan Stanley & Co. LLC

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley & Co. LLC
Date:	08/07/2025

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many Chemomab shares does Morgan Stanley now own?

13,213,260 shares, representing 3.2 % of the outstanding class, all with shared voting/dispositive power.

What percentage of Chemomab (CMMB) is held by Morgan Stanley & Co. LLC?

The subsidiary holds 9,275,360 shares, or 2.2 % of the class.

Why was this Schedule 13G/A filed?

Ownership fell below the 5 % reporting threshold, requiring an amended filing under SEC Rule 13d-2.

Does Morgan Stanley still have sole voting control over any Chemomab shares?

No. The filing reports 0 shares with sole voting or dispositive power; all powers are shared.

Is Morgan Stanley seeking to influence Chemomab’s management?

The certification states the shares are held in the ordinary course and not for the purpose of influencing control.